Enter your ZIP code:

Please enter a 5 digit zipcode
No results...

Entering your zip code helps us to provide information and results that are more relevant to you.

Your privacy is important to us. By continuing, you agree to our Privacy Policy.





LoTamRandomPhIII LowDosTamoxifenSelectPa w/MolecularLowRiskEarlyStageBreastCa

Cancer
Ritesh Parajuli
LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-Risk Early-Stage Breast Cancer
Breast

Study Description

PRIMARY OBJECTIVE:

To evaluate whether the recurrence-free interval (RFI) with low-dose tamoxifen is non-inferior to standard-of-care endocrine therapy among post-menopausal women with early-stage, low molecular risk breast cancer.

Eligibility

KEY ELIGIBILITY CRITERIA:

  1. Histologically confirmed unilateral invasive adenocarcinoma, HER2 negative
  2. Tumor size not larger than 3 cm
  3. No definitive clinical or radiologic evidence of metastatic disease
  4. Must be intending to take at least 5 years of endocrine therapy
  5. Confirmed postmenopausal status
  6. No abnormal or dysfunctional uterine bleeding within 1 year of study enrollment
  7. No concurrent treatment with any endocrine therapy for breast cancer prevention or osteoporosis, including raloxifene, tamoxifen, or other selective estrogen receptor modulator.
A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.